%0 Journal Article %A Karlowsky, James A. %A Zhanel, George G. %A Hammond, Greg W. %A Rubinstein, Ethan %A Wylie, John %A Du, Tim %A Mulvey, Michael R. %A Alfa, Michelle J. %T Multidrug-resistant North American pulsotype 2 Clostridium difficile was the predominant toxigenic hospital-acquired strain in the province of Manitoba, Canada, in 2006–2007 %D 2012 %J Journal of Medical Microbiology, %V 61 %N 5 %P 693-700 %@ 1473-5644 %R https://doi.org/10.1099/jmm.0.041053-0 %I Microbiology Society, %X The objective of the current study was to determine whether the antimicrobial susceptibility profile or genotype of hospital-acquired isolates of Clostridium difficile differed from isolates causing community-acquired disease. Five hundred diarrhoeal stool samples (one >2 ml sample per patient) from patients across Manitoba, Canada, in 2006–2007 that were reported as C. difficile toxin positive were cultured, resulting in 432 isolates of toxin-positive C. difficile for analysis. Of these 432 isolates, acquisition status could be determined for 235 (54.4 %); 182 (77.4 %) isolates were hospital acquired and 53 (22.6 %) were community acquired. North American pulsotype (NAP) designations based on SmaI PFGE could be defined for 52.3 % of the 432 isolates, with NAP2 (n = 122) being the most common. Ninety-one per cent (71/78) of NAP2 isolates were recovered from patients with hospital-acquired C. difficile disease. Other NAP types and isolates with non-NAP-type PFGE patterns were less frequently associated with hospital-acquired disease. Community-acquired disease (35.3 % of isolates) was associated with a wide variety of NAP types. NAP2 isolates were homogeneous (85.5 % had SmaI PFGE pattern 0003) and demonstrated low susceptibility to moxifloxacin (6.6 %) and clindamycin (1.6 %) compared with non-NAP2 isolates (64.1–93.2 % moxifloxacin susceptible; 14.1–28.2 % clindamycin susceptible). All isolates of C. difficile in Manitoba were susceptible to metronidazole, piperacillin–tazobactam, amoxicillin–clavulanate and meropenem. NAP2 isolates of toxigenic C. difficile were approximately three times more common than NAP1 isolates (28.2 vs 9.1 %) in Manitoba in 2006–2007, and these isolates demonstrated high levels of clonality and multidrug resistance, and were associated with hospital acquisition. %U https://www.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.041053-0